DNA methylation and histone modifications in patients with cancer: Potential prognostic and therapeutic targets

Methods in Molecular Biology

Volumn 361, Issue , 2007, Pages 25-62

  Herranz, Michel ^a   Esteller, Manel ^a  

^a NONE

Author keywords

Cancer epigenetics; DNA methylation; Histone modifications; Prognosis; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE; TUMOR SUPPRESSOR PROTEIN;

ACETYLATION; BIOSYNTHESIS; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; METHYLATION; NEOPLASM; PROGNOSIS; PROTEIN PROCESSING; REVIEW;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; METHYLATION; NEOPLASMS; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34548480199     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-208-4:25     Document Type: Article

References (146)

1. Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., and Richmond, T. J. (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-260.
2. Strahl, B. D. and Allis, C. D. (2000) The language of covalent histone modifications. Nature 403, 41-45.
3. Davie, J. K. and Dent, S. Y (2004) Histone modifications in corepressor functions. Curr. Top. Dev. Biol. 59, 145-163.
4. Pickart, C. M. (2001) Ubiquitin enters the new millennium. Mol. Cell. 8, 499-504.
5. Kondo, Y., Shen, L., and Issa, J. P. (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol. 23, 206-215.
6. Shiio, Y and Eisenman, R. N. (2003) Histone sumoylation is associated with transcriptional repression. Proc. Natl. Acad. Sci. USA 100, 13,225-13,230.
7. Rice, J. C. and Allis, C. D. (2001) Code of silence. Nature 414, 258-261.
8. Yoder, J. A., Soman, N. S., Verdine, G. L., and Bestor, T. H. (1997) DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanismbased probe. J. Mol. Biol. 270, 385-395.
9. Esteller, M., Fraga, M. F., Guo, M., et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10, 3001-3007.
10. Antequera, F. and Bird, A. (1993) Number of CpG islands and genes in human and mouse. Proc. Natl. Acad. Sci. USA 90, 11,995-11,999.
11. Bestor, T. H. (2000) The DNA methyltransferases of mammals. Hum. Mol. Genet. 9, 2395-2402.
12. Bird, A. P. and Wolffe, A. P. (1999) Methylation-induced repression-belts, braces, and chromatin. Cell 99, 451-454.
13. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. (2001) A gene hypermethylation profile of human cancer. Cancer. Res. 61, 3225-3229.
14. Paz, M. F., Wei, S., Cigudosa, J. C., et al. (2003) Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum. Mol. Genet. 12, 2209-2219.
15. Razin, A. (1998) CpG methylation, chromatin structure and gene silencing-a three-way connection. Embo. J. 17, 4905-4908.
16. Cervoni, N. and Szyf, M. (2001) Demethylase activity is directed by histone acetylation. J. Biol. Chem. 276, 40,778-40,787.
17. Cervoni, N., Detich, N., Seo, S. B., Chakravarti, D., and Szyf, M. (2002) The oncoprotein Set/TAF-lbeta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J. Biol. Chem. 277, 25,026-25,031.
18. Esteller, M., Cordon-Cardo, C., Corn, P. G., et al. (2001) p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 61, 2816-2821.
19. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S. B., and Brown, R. (2000) Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039-6044.
20. Esteller, M., Garcia-Foncillas, J., Andion, E., et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354.
21. Esteller, M., Gaidano, G., Goodman, S. N., et al. (2002) Hypermethylation of the DNA repair gene 0(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94, 26-32.
22. Plass, C., Shibata, H., Kalcheva, I., et al. (1996) Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M. Nat. Genet. 14, 106-109.
23. Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. (1996) Hypermethylationassociated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56, 722-727.
24. Jones, P. A. and Baylin, S. B. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428.
25. Robertson, K. D. and Jones, P. A. (2000) DNA methylation: past, present and future directions. Carcinogenesis 21, 461-467.
26. Robertson K. D. and Jones, P. A. (1999) The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol. 18, 6457-6473.
27. Esteller, M., Tortola, S., Toyota, M., et al. (2000) Hypermethylation- associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60, 129-133.
28. Esteller, M., Cordon-Cardo, C., Corn, P. G., et al. (2001) P14ARF silencing by promoter hypermethylation mediated abnormal intracellular localization of MDM2. Cancer Res. 61, 2816-2821.
29. Corn, P. G., Kuerbitz, S. J., Van Noesel, M. M., et al. (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res. 59, 3352-3356.
30. Herman, J. G., Merlo, A., Mao, L. et al. (1995) Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525-4530.
31. Merlo, A., Herman, J. G., Mao, L., et al. (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1, 686-692.
32. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., et al. (1995) Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531-4535.
33. Greger, V., Passarge, E., Hopping, W., Messmer, E., and Horsthemke, B. (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83, 155-158.
34. Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. (1996) Hypermethylationassociated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56, 722-727.
35. Kane, M. F., Loda, M., Gaida, G. M., et al. (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808-811.
36. Herman, J. G., Umar, A., Polyak, K., et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95, 6870-6875.
37. Esteller, M., Levine, R., Hedrick, L., Ellenson, L. H., and Herman, J. G. (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinoma. Oncogene 17, 2413-2417.
38. Esteller, M., Lluis, C., Matias-Guiu, X., et al. (1999) HMLH1 promoter hypermethylation is an early event in endometrial tumorigenesis. Am. J. Pathol. 155, 1767-1772.
39. Fleisher, A. S., Esteller, M., Wang, S., et al. (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 59, 1090-1095.
40. Esteller, M., Hamilton, S. R., Burger, P. C., et al. (1999) Inactivation of the DNA repair gene O-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797.
41. Esteller, M., Toyota, M., Sanchez-Cespedes, M., et al. (2000) Inactivation of the DNA repair gene 06-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60, 2368-2371.
42. Esteller, M., Risques, R. A., Toyota, M., et al. (2001) Promoter hypermethylation of the DNA repair gene O-Methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis, Cancer Res. 61, 4689-4692.
43. Mizuno, K., Osada, H., Konishi, H., et al. (2002) Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21, 2328-2333.
44. Esteller, M., Silva, J. M., Dominguez, G., et al. (2000) Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564-569.
45. Hedelfank, I., Duggan, D., Chen, Y., et al. (2001) Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 343, 539-548.
46. Johnstone, R. W (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299.
47. Jenuwein, T. and Allis, C. D. (2001) Translating the histone code. Science 293, 1074-1080.
48. Winston, F. and Allis, C. D. (1999) The bromodomain: a chromatin-targeting module? Nat. Struct. Biol. 6, 601-604.
49. Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., and Zhou, M. M. (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496.
50. Fahrner, J. A., Eguchi, S., Herman, J. G., and Baylin, S. B. (2002) Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62, 7213-7218.
51. Nguyen, C. T., Weisenberger, D. J., Velicescu, M., et al. (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 62, 6456-6461.
52. Strahl, B. D., Ohba, R., Cook, R. G., and Allis, C. D. (1999) Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc. Natl. Acad. Sci. USA 96, 14,967-14,972.
53. Schubeler, D., MacAlpine, D. M., Scalzo, D., et al. (2004) The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 18, 1263-1271.
54. Cuthbert, G. L., Daujat, S., Snowden, A. W., et al. (2004). Histone deimination antagonizes arginine methylation. Cell 118, 545-553.
55. Workman, J. L. and Abmayr, S. M. (2004) Histone H3 variants and modifications on transcribed genes. Proc. Natl. Acad. Sci. USA 101, 1429-1430.
56. Cao, R. and Zhang, Y. (2004) SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57-67.
57. Hamamoto, R., Furukawa, Y., Morita, M., et al. (2004) SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6, 731-740.
58. Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
59. Vogelstein, B. (1990) Cancer. A deadly inheritance. Nature 348, 681-682.
60. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. (2001) A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229.
61. Esteller, M. (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427-5440.
62. Fraga, M. F. and Esteller, M. (2002) DNA methylation: a profile of methods and applications. BioTechniques 33, 632-649.
63. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. (1999) Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat. Genet. 21, 103-107.
64. Suzuki, H., Gabrielson, E., Chen, W., et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31, 141-149.
65. Yamashita, K., Upadhyay, S., Osada, M., et al. (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485-495.
66. Baylin, S. B. and Herman, J. G. (2001) Promoter hypermethylation-can this change alone ever designate true tumor suppressor gene function? J. Natl. Cancer Inst. 93, 664-665.
67. Chen, R. Z., Pettersson, U., Beard, C., Jackson-Grusby, L., and Jaenisch, R. (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395, 89-93.
68. Wijermans, P. W., Krulder, J. W., Huijgens, P. C., and Neve, P. (1997) Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11, 1-5.
69. Schwartsmann, G., Fernandes, M. S., Schaan, M. D., et al. (1997) Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 11, S28-S31.
70. Alaminos, M., Davalos, V., Cheung, N. K., Gerald, W. L., and Esteller, M. (2004) Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J. Natl. Cancer Inst. 96, 1208-1219.
71. Ahrendt, S. A., Chow, J. T., Xu, L. H., et al. (1999) Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst. 91, 332-339.
72. Sanchez-Cespedes, M., Esteller, M., Hibi, K., et al. (1999) Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin. Cancer Res. 5, 2450-2454.
73. Palmisano, W. A., Divine, K. K., Saccomanno, G., et al. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958.
74. Cairns, P., Esteller, M., Herman, J. G., et al. (2001) Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 1, 2727-2730.
75. Goessl, C., Muller, M., and Miller, K. (2000) Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis. 3, S17.
76. Evron, E., Dooley, W. C., Umbricht, C. B., et al. (2001) Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357, 1335-1336.
77. Rosas, S. L., Koch, W., da Costa Carvalho, M. G., et al. (2001) Promoter hypermethylation patterns of p16, 06-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939-942.
78. Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., and Herman, J. G. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70.
79. Kawakami, K., Brabender, J., Lord, R. V., et al. (2000) Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92, 1805-1811.
80. Grady, W. M., Rajput, A., Lutterbaugh, J. D., and Markowitz, S. D. (2001) Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61, 900-902.
81. Esteller, M. and Herman, J. G. (2004) Generating mutations but providing chemosensitivity: the role of 06-methylguanine DNA methyltransferase in human cancer. Oncogene 23, 1-8.
82. Ottaviano, Y L., Issa, J. P., Pari, F. F., Smith, H. S., Baylin, S. B., and Davidson, N. E. (1994) Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54, 2552-2555.
83. Ballestar, E. and Esteller, M. (2002) The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23, 1103-1109.
84. Fraga, M. F., Uriol, E., and Diego, L. B., et al. (2002) High performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 23, 1677-1681.
85. Paz, M. F., Fraga, M. F., Avila, S., et al. (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63, 1114-1121.
86. Daskalakis, M., Nguyen, T. T., Nguyen, C., et al. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100, 2957-2964.
87. Christman, J. K. (2002) 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483-5495.
88. Lo Coco, F., Zelent, A., Kimchi, A., et al. (2002) Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. Cancer Res. 62, 5618-5621.
89. Soengas, M. S., Capodieci, P., Polsky, D., et al. (2001) Inactivation of the apoptosis effector Apaf-1 in melanoma. Nature 409, 207-211.
90. Spotswood, H. T. and Turner, B. M. (2002) An increasingly complex code. J. Clin. Invest. 110, 577-582.
91. Peterson, C. L. and Laniel, M. A. (2004) Histones and histone modifications. Curr. Biol. 14, R546-R551.
92. Hake, S. B., Xiao, A., and Allis, C. D. (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 90, 761-769.
93. Hubbert, C., Guardiola, A., Shao, R., et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458.
94. Marks, P. A., Miller, T., and Richon, V. M. (2003) Histone deacetylases. Curr. Opin. Pharmacol. 3, 344-351.
95. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., and van Kuilenburg, A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749.
96. Marks, P., Rifkind, R. A., Richon, V M., Breslow, R., Miller, T., and Kelly, W. K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202.
97. Deckert, J. and Struhl, K. (2001) Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol. Cell. Biol. 21, 2726-2735.
98. Butler, L. M., Zhou, X., Xu, W S., et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99, 11,700-11,705.
99. Dehm, S. M., Hilton, T. L., Wang, E. H., and Bonham, K. (2004) SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Mol. Cell. Biol. 24, 2296-2307.
100. Hirsch, C. L. and Bonham, K. (2004) Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett. 570, 37-40.
101. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17,174-17,179.
102. Remiszewski, S. W., Sambucetti, L. C., Bair, K. W., et al. (2003) N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4- [[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J. Med. Chem. 46, 4609-4624.
103. Atadja, P., Gao, L., Kwon, P., et al. (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 64, 689-695.
104. Plumb, J. A., Finn, P. W., Williams, R. J., et al. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2, 721-728.
105. Sealy, L. and Chalkley, R. (1978) The effect of sodium butyrate on histone modification. Cell 14, 115-121.
106. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., and Klein, P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36,734-36,741.
107. Gottlicher, M., Minucci, S., Zhu, P., et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978.
108. Lea, M. A. and Tulsyan, N. (1995) Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res. 15, 879-883.
109. Gore, S. D., Weng, L. J., Figg, W. D., et al. (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8, 963-970.
110. Patnaik, A., Rowinsky, E. K., Villalona, M. A., et al. (2002) A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8, 2142-2148.
111. Saito, A., Yamashita, T., Mariko, Y., et al. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592-4597.
112. Fournel, M., Trachy-Bourget, M. C., Yan, P. T., et al. (2002) Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 62, 4325-4330.
113. Kraker, A. J., Mizzen, C. A., Hartl, B. G., Miin, J., Allis, C. D., and Merriman, R. L. (2003) Modulation of histone acetylation by [4-(acetylamino)-N- (2-aminophenyl)benzamide] in HCT-8 colon carcinoma. Mol. Cancer Ther. 2, 401-408.
114. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98, 87-92.
115. Darkin-Rattray, S. J., Gurnett, A. M., Myers, R. W., et al. (1996) Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 93, 13,143-13,147.
116. Murphy, J. P., McAleer, J. P., Uglialoro, A., et al. (2000) Histone deacetylase inhibitors and cell proliferation in pea root meristems. Phytochemistry 55, 11-18.
117. Murray, P. J., Kranz, M., Ladlow, M., et al. (2001) The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. Bioorg. Med. Chem. Lett. 11, 773-776.
118. Hong, J., Ishihara, K., Yamaki, K., et al. (2003) Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells. Cancer Lett. 189, 197-206.
119. Mei, S., Ho, A. D., and Mahlknecht, U. (2004) Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int. J. Oncol. 25, 1509-1519.
120. Espino, P. S., Drobic, B., Dunn, K. L., and Davie, J. R. (2005) Histone modifications as a platform for cancer therapy. J. Cell. Biochem. 94, 1088-1102.
121. Guasconi, V. and Ait-Si-Ali, S. (2004) Chromatin dynamics and cancer. Cancer Biol. Then 3, 825-830.
122. Rouaux, C., Loeffler, J. P., and Boutillier, A. L. (2004) Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem. Pharmacol. 68, 1157-1164.
123. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826.
124. Esteller, M., Fraga, M. F., Guo, M., et al. (2001) DNA methylation patterns in hereditary human cancer mimics sporadic tumorigenesis. Hum. Mol. Genet. 10, 3001-3007.
125. Herman, J. G., Umar, A., Polyak, K., et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95, 6870-6875.
126. Esteller, M., Levine, R., Baylin, S. B., Ellenson, L. H., and Herman, J. G. (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17, 2413-2417.
127. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., and Herman, J. G. (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797.
128. Hedenfalk, I., Duggan, D., Chen, Y., et al. (2001) Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539-548.
129. Myohanen, S. K., Baylin, S. B., and Herman, J. G. (1998) Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58, 591-593.
130. Yeager, T. R., DeVries, S., Jarrard, D. F., et al. (1998) Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 12, 163-174.
131. Esteller, M., Sparks, A., Toyota, M., et al. (2000) Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60, 4366-4371.
132. Cote, S. and Momparler, R. L. (1997) Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs 8, 56-61.
133. Virmani, A. K., Rathi, A., Zochbauer-Muller, S., et al. (2000) Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92, 1303-1307.
134. Esteller, M., Guo, M., Moreno, V., et al. (2002) Hypermethylation- associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 62, 5902-5905.
135. Villar-Garea, A. and Esteller, M. (2003) DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr. Drug Metab. 4, 11-31.
136. Cheng, J. C., Matsen, C. B., Gonzales, F. A., et al. (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 95, 399-409.
137. Cheng, J. C., Yoo, C. B., Weisenberger, D. J., et al. (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158.
138. Lin, X., Asgari, K., Putzi, M. J., et al. (2001) Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61, 8611-8616.
139. Villar-Garea, A., Fraga, M. F., Espada, J., and Esteller, M. (2003) Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 63, 4984-4989.
140. Pinto, A., Zagonel, V., Attadia, V., et al. (1989) 5-Aza-2-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 4, 28-32.
141. Silverman, L. R., Holland, J. F., Weinberg, R. S., et al. (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1, 21-29.
142. Silverman, L. R., Demakos, E. P., Peterson, B. L., et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429-2440.
143. Turner, B. M. (2002) Cellular memory and the histone code. Cell 111, 285-291.
144. Bannister, A. J. and Kouzarides, T. (2004) Histone methylation: recognizing the methyl mark. Methods Enzymol. 376, 269-288.
145. Ng, H. H., Zhang, Y., Hendrich, B., et al. (1999) MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nature Genet. 23, 58-61.
146. Wade, P. A., Gegonne, A., Jones, P. L., Ballestar, E., Aubry, F., and Wolffe, A. P. (1999) Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nature Genet. 23, 62-66.